Climb Bio, Inc.

Public

MassachusettsBiotechhttps://climbbio.com/

Last Round

Private Placement

May 4, 2026

Total Funding Raised

$110.08M

Company Overview

Eliem Therapeutics (NAS: CLYM) is a biotechnology company focused on developing therapeutics for immune-mediated diseases, with its lead product candidate, budoprutug, being an anti-CD19 monoclonal antibody that shows promise in treating various B-cell-mediated conditions through B-cell depletion.

Sector

Biotech

AI Layer

Non-AI

Keywords

anti-CD19 monoclonal antibodyautoimmune disease therapeuticsCD19-positive B cell depletion therapytherapeutics for systemic lupus erythematosus (SLE)therapeutics for immune thrombocytopenia (ITP)autoantibody-mediated disease treatmentbiopharmaceutical asset acquisition and developmentclinical-stage antibody developmenttherapeutics for membranous nephropathy (MN)

Climb Bio, Inc. Comps

Public and private peers based on sector, stage, and business model.

Climb Bio, Inc. comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Climb Bio, Inc. Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Private Placement	May 4, 2026

View all Funding Rounds

Key People

Founding team and executive leadership

Aoife Brennan

President And CEO

Executive Team

Susan Altschuller

Chief Financial Officer

Executive Team

Climb Bio, Inc. Investors

Notable investors and investment history

Climb Bio, Inc. investors
Investor	Rounds
Redmile Group	Private Placement
ADAR1 Capital Management	Private Placement
RA Capital Management	Private Placement
Ally Bridge Group	Private Placement
Adage Capital Partners, L.P.	Private Placement
Driehaus Capital Management	Private Placement
Cormorant Asset Management	Private Placement

View all Investors

Climb Bio, Inc. Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Climb Bio, Inc. Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersMassachusetts

Employee Range37

Year Founded2018

Last FundingMay 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.